心血管疾病中的新兴治疗策略
Rajinderpal Singh1, Sohbat Kaur Chandi1, Seerat Sran2
1Internal Medicine, Government Medical College Amritsar, Amritsar, IND.
Cureus
|August 12, 2024
概括
创新的心血管疗法,包括新药,基因疗法和医疗设备,为更好的患者结果提供了希望. 解决成本和监管等挑战是改变全球心血管保健的关键.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 生物技术是生物技术.
- 医疗器械 医疗器械
- 个性化医疗是个性化的医疗.
背景情况:
- 心血管疾病 (CVD) 是全球主要的死亡原因,每年有近2000万人死亡.
- 传统的心血管疾病治疗因人口老龄化和生活方式因素而面临局限性,需要新的方法.
- 全球心血管疾病的患病率不断上升,凸显了对先进和有效的治疗策略的迫切需要.
研究的目的:
- 审查和突出针对心血管疾病 (CVD) 的创新治疗策略.
- 讨论心血管保健领域新兴的药物,生物和技术进步.
- 探索个性化医学的潜力,并确定采用新型心血管疾病治疗的挑战.
主要方法:
- 对新兴药物治疗方法的审查,如PCSK9和SGLT2抑制剂.
- 分析先进的生物疗法,包括基因,干细胞和基于RNA的治疗方法.
- 评估创新的医疗器械,微创手术和可穿戴技术.
- 探索由遗传分析和生物标志物驱动的个性化医疗方法.
主要成果:
- 新兴药理学药剂显著降低心血管事件和死亡率.
- 生物疗法在修复和再生心血管组织方面表现有前途.
- 先进的设备和技术使得早期诊断,持续监测和远程患者护理成为可能.
- 个性化医疗提高了治疗效率,并最大限度地减少了不良影响.
结论:
- 创新疗法,包括药物,生物和技术进步,具有巨大的潜力,可以改变心血管保健.
- 克服监管障碍,成本,可访问性和道德考虑等挑战对于广泛采用至关重要.
- 跨学科的合作和持续的研究对于加速下一代心血管疾病治疗的开发和实施至关重要.
- 通过新兴疗法的战略整合,可以实现个性化,有效和可访问的心血管护理的未来.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
406
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
406
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
2.1K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.1K
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
425
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
425
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
474
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
474
01:22Heart Failure Drugs: β-Blockers
326
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
326
01:16Antianginal Drugs: Nitrates and β-Blockers
557
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
557